Key Highlights
- EMA’s CHMP backs a paradigm shift: Sanofi’s Sarclisa receives positive opinion for frontline induction use in transplant-eligible NDMM—marking a pivotal regulatory milestone in European oncology.
- First-of-its-kind Phase 3 validation: GMMG-HD7 is the first to demonstrate enhanced MRD negativity and PFS benefits with anti-CD38-based induction therapy in eligible NDMM patients.
- Sanofi’s AI-powered oncology momentum: A fourth EU indication and second global frontline approval would accelerate Sarclisa’s role in high-impact, early-line myeloma care.
EMA’s CHMP Endorses Sarclisa-VRd for Frontline Multiple Myeloma in Transplant-Eligible Adults
On June 23, 2025, Sanofi announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as induction treatment for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant. This decision brings Sarclisa a step closer to its fourth indication in the EU and solidifies its role as a key agent in addressing early-stage, high-risk myeloma.
GMMG-HD7 Sets New Benchmarks with Enhanced MRD and PFS Outcomes
The CHMP’s recommendation is grounded in the results from the GMMG-HD7 Phase 3 study—the first randomized trial to demonstrate superior MRD negativity and significant progression-free survival benefit with a CD38 antibody in a transplant-eligible NDMM setting. Patients receiving the Sarclisa-VRd regimen showed a deeper therapeutic response post-induction, supporting its potential to reshape clinical protocols and deepen remission at critical treatment junctures.
From Relapsed to Frontline: Sanofi Advances Early Intervention in Multiple Myeloma
Sarclisa has established its value in relapsed/refractory settings, but this recommendation signals its strategic expansion into frontline therapy. If approved, this will mark Sarclisa’s second global indication in newly diagnosed patients—this time for those eligible for transplant—offering clinicians a powerful new option at the onset of disease and reinforcing Sanofi’s commitment to redefining the myeloma treatment pathway from the start.
AI-Powered Innovation Meets Unmet Clinical Needs in Oncology
Sanofi’s AI-integrated development model is accelerating the delivery of high-impact therapies like Sarclisa. Collaborating with Germany’s GMMG study group, Sanofi backed a rigorous, dual-randomized trial design aimed at deep molecular remission. The CHMP endorsement not only validates this data-driven approach but also underscores the importance of advanced analytics in shaping next-generation cancer therapeutics—aligning science, speed, and patient outcomes.
About Sanofi
Sanofi is a global, R&D-driven biopharmaceutical company committed to advancing science to improve lives. Leveraging deep expertise in immunology, oncology, and rare diseases—and powered by AI—Sanofi is focused on delivering first- and best-in-class therapies for patients worldwide. The company is listed on EURONEXT (SAN) and NASDAQ (SNY).
About Sarclisa (isatuximab)
Sarclisa is a monoclonal antibody targeting CD38, a surface protein commonly expressed on multiple myeloma cells. It is designed to induce programmed tumor cell death and immune-mediated cytotoxicity, disrupting disease progression in patients with multiple myeloma (MM).
Currently approved in more than 50 countries—including the US, EU, Japan, and China—Sarclisa is indicated across multiple lines of therapy for relapsed/refractory MM (R/R MM) and for newly diagnosed MM (NDMM) in transplant-ineligible patients.
By